Looking Into the Future
HER2-Directed Therapies in Advanced Gastric and Colorectal Cancer

FRIDAY, 5 JULY 2019
REGISTRATION AND LUNCH: 12:55 | PRESENTATION: 13:10 – 14:10
VENUE: THE INTERNATIONAL CONVENTION CENTER OF BARCELONA | ROOM: 111

www.medscape.org/sympo/her2therapy-gastric-crc-registration

FACULTY

Takayuki Yoshino, MD, PhD
Director
Gastroenterology and Gastrointestinal Oncology
National Cancer Center Hospital East
Chiba, Japan

Florian Lordick, MD, PhD
Director and Professor of Oncology
1st Medical Department and University Cancer Center (UCCL)
University Hospital Leipzig
Leipzig, Germany

Salah-Eddin Al-Batran, MD
Director of the Institute of Clinical Cancer Research
Director of GI Oncology
Krankenhaus Nordwest-University Cancer Center
Frankfurt, Germany

Supported by an independent educational grant from Daiichi Sankyo.
AGENDA

12:55 – 13:10
Registration and Lunch

13:10 – 13:15
Welcome and Introductions
Takayuki Yoshino, MD, PhD

13:15 – 13:30
HER2 Testing: Informing Clinical Application of HER2-Directed Therapy in Gastric and Colorectal Cancer
Florian Lordick, MD, PhD

13:30 – 13:45
HER2-Directed Therapy in Gastric Cancer: Looking Into Improving Outcomes
Salah-Eddin Al-Batran, MD

13:45 – 14:00
HER2-Directed Therapy in CRC: Looking Into the Future
Takayuki Yoshino, MD, PhD

14:00 – 14:10
Panel and Audience Discussion

14:10
Adjourn

TARGET AUDIENCE
This activity is intended for a global audience of oncologists/hematologists, gastroenterologists, surgeons, pathologists, and internal medicine physicians/PCPs.

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

Have increased knowledge regarding the

• Use of HER2 testing in gastric and colorectal cancer
• HER2-directed therapies available and in development for the management of patients with advanced gastric and colorectal cancer
• Most recent efficacy and safety data from clinical trials with HER2-directed therapies
• Mechanisms of resistance to HER2-directed therapies and strategies to overcome these

Demonstrate greater confidence in their ability to

• Understand the potential therapeutic role and place of new HER2-directed therapies in the treatment algorithm for gastric and colorectal cancer

ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLAIMER
Satellite symposium held in conjunction with the ESMO 21st World Congress on Gastrointestinal Cancer.

This symposium is not an official part of the World Congress scientific program, nor is it organized or endorsed by Imedex.